GAT1 antibodies target the solute carrier family 6 member 1 (SLC6A1), a Na+/Cl−-dependent transporter responsible for GABA uptake at synaptic and extrasynaptic sites . Key features include:
Molecular Weight: 67 kDa (canonical) , though some antibodies detect truncated forms (e.g., 42 kDa) .
Epitopes: Most antibodies recognize extracellular domains (e.g., Alomone Labs’ AGT-001) or C-terminal regions (e.g., Proteintech’s 20298-1-AP) .
GAT1 antibodies are widely used in neuroscience research:
Neurons: Predominantly in GABAergic interneurons and some pyramidal neurons .
Astrocytes: 43% of cortical GAT1+ profiles are astrocytic processes, often near synapses .
Oligodendrocytes and Microglia: Functional GAT1 expression confirmed via tiagabine-sensitive GABA uptake .
GABA Regulation: GAT1 deficiency in mice increases extracellular GABA, enhancing tonic inhibition in CA1 pyramidal cells .
Disease Links: Implicated in epilepsy, schizophrenia, and Parkinson’s disease via dysregulated GABA signaling .
Antigen Retrieval: Citrate buffer (pH 6.0) or TE buffer (pH 9.0) recommended for IHC .
Validation: Knockout models (e.g., GAT1-KO mice) and preadsorption controls critical for specificity .
Recent studies challenge the neuron-centric view of GAT1, highlighting its roles in glial cells: